Skip to main content
SpringerLink
Log in

Treatment of Early Favorable Hodgkin Lymphoma

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Early favorable Hodgkin lymphoma is defined as Ann Arbor stage I and II Hodgkin lymphoma without clinical risk factors. Historically, early favorable Hodgkin lymphoma became highly curable with large radiotherapy fields but at the cost of high early and late toxicity resulting in reduced long-term survival. The successful introduction of multiagent chemotherapy in Hodgkin lymphoma made it possible to combine chemotherapy with radiotherapy in smaller doses and fields. Last decades, efforts have been made to find optimal chemotherapy treatment with limited cycles (2–3) of ABVD combined with limited dose (20–30 Gy) involved-field and involved-node radiotherapy. Most recently, trials investigating PET response-adapted treatment showed that a significant progression-free survival benefit can be achieved by intensification of treatment in case of interim PET positivity after 2–3 cycles of ABVD. On the other hand, omission of radiotherapy in case of a negative interim PET results in poorer progression-free survival of about 7–12% with similar overall survival. Long-term effects of omitting radiotherapy on secondary malignancies and cardiovascular outcomes need to be awaited. A case-by-case weighing of expected long-term risk of current radiotherapy regimens against the limited decrease in progression-free survival should be performed to choose treatment with best short- and long-term outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31:1860–1861

    CAS  PubMed  Google Scholar 

  2. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636

    Article  CAS  PubMed  Google Scholar 

  3. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging Subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 25:571–578

    Article  PubMed  Google Scholar 

  4. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586

    Article  PubMed  Google Scholar 

  5. El-Galaly TC, d’Amore F, Mylam KJ, de Nully Brown P, Bøgsted M, Bukh A et al (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment naïve patients with Hodgkin lymphoma. J Clin Oncol 30:4508–4514

    Article  PubMed  Google Scholar 

  6. Specht L, Nissen NI (1988) Hodgkin’s disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavourable combination. Eur J Haematol 40:396–402

    Article  CAS  PubMed  Google Scholar 

  7. Sasse S, Goergen H, Plütschow A, Böll B, Eichenauer DA, Fuchs M et al (2018) Outcome of patients with early-stage infradiaphragmatic Hodgkin lymphoma: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol 36:2603–2611

    Article  CAS  PubMed  Google Scholar 

  8. Specht L (1996) Prognostic factors in Hodgkin’s disease. Semin Radiat Oncol 6:146–161

    Article  CAS  PubMed  Google Scholar 

  9. Tubiana M, Henry-Amar M, van der Werf-Messing B, Henry J, Abbatucci J, Burgers M et al (1985) A multivariate analysis of prognostic factors in early stage Hodgkin’s disease. Int J Radiat Oncol Biol Phys 11:23–30

    Article  CAS  PubMed  Google Scholar 

  10. Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F et al (2007) Chemotherapy plus involved-field radiation in early stage Hodgkin’s disease. N Engl J Med 357:1916–1927

    Article  CAS  PubMed  Google Scholar 

  11. Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C et al (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25:3495–3502

    Article  CAS  PubMed  Google Scholar 

  12. Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R et al (2018) Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 131:1456–1463

    Article  CAS  PubMed  Google Scholar 

  13. Hoppe RT, Coleman CN, Cox RS, Rosenberg SA, Kaplan HS (1982) The management of stage I–II Hodgkin’s disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 59:455–465

    Article  CAS  PubMed  Google Scholar 

  14. Gospodarowicz MK, Sutcliffe SB, Clark RM, Dembo AJ, Fitzpatrick PJ, Munro AJ et al (1992) Analysis of supradiaphragmatic clinical stage I and II Hodgkin’s disease treated with radiation alone. Int J Radiat Oncol Biol Phys 22:859–865

    Article  CAS  PubMed  Google Scholar 

  15. Raemaekers J, Kluin-Nelemans H, Teodorovic I, Meerwaldt C, Noordijk E, Thomas J et al (2002) The achievements of the EORTC lymphoma group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38(Suppl 4):S107–S113

    Article  PubMed  Google Scholar 

  16. Tubiana M, Henry-Amar M, Carde P, Burgers JM, Hayat M, Van der Schueren E et al (1989) Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC lymphoma group controlled clinical trials: 1964–1987. Blood 73:47–56

    Article  CAS  PubMed  Google Scholar 

  17. Tubiana M, Henry-Amar M, Hayat M, Breur K, van der Werf-Messing B, Burgers M (1979) Long-term results of the E.O.R.T.C. randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin’s disease. Eur J Cancer 15:645–657

    Article  CAS  PubMed  Google Scholar 

  18. Tubiana M, Hayat M, Henry-Amar M, Breur K, van der Werf MB, Burgers M (1981) Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin’s disease. Eur J Cancer 17:355–363

    Article  CAS  PubMed  Google Scholar 

  19. Carde P, Burgers JM, Henry-Amar M, Hayat M, Sizoo W, Van der Schueren E et al (1988) Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 6:239–252

    Article  CAS  PubMed  Google Scholar 

  20. Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJ et al (1993) Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer lymphoma cooperative group. J Clin Oncol 11:2258–2272

    Article  CAS  PubMed  Google Scholar 

  21. Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC et al (2006) Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128–3135

    Article  PubMed  Google Scholar 

  22. Duhmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Ruhl U et al (2001) Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905–2914

    Article  CAS  PubMed  Google Scholar 

  23. Specht L, Gray RG, Clarke MJ, Peto R (1998) International Hodgkin’s disease collaborative group. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 16:830–843

    Article  CAS  PubMed  Google Scholar 

  24. Horwich A, Specht L, Ashley S (1997) Survival analysis of patients with clinical stages I or II Hodgkin’s disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 33:848–853

    Article  CAS  PubMed  Google Scholar 

  25. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE (2003) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21:3431–3439

    Article  PubMed  Google Scholar 

  26. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC et al (2002) Long-term survival and competing causes of death in patients with early stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 20:2101–2108

    Article  PubMed  Google Scholar 

  27. Favier O, Heutte N, Stamatoullas-Bastard A, Carde P, Van’t Veer MB, Aleman BM et al (2009) Survival after HL: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer 115:1680–1691

    Article  PubMed  Google Scholar 

  28. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484

    Article  CAS  PubMed  Google Scholar 

  29. Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH et al (2001) Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol 19:4238–4244

    Article  CAS  PubMed  Google Scholar 

  30. Horning SJ, Hoppe RT, Mason J, Brown BW, Hancock SL, Baer D et al (1997) Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin’s disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 15:1736–1744

    Article  CAS  PubMed  Google Scholar 

  31. Zittoun R, Audebert A, Hoerni B, Bernadou A, Krulik M, Rojouan J et al (1985) Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 3:207–214

    Article  CAS  PubMed  Google Scholar 

  32. Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC et al (2006) Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128–3135

    Article  PubMed  Google Scholar 

  33. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652

    Article  CAS  PubMed  Google Scholar 

  34. Behringer K, Görgen H, Hitz F, Zijlstra JM, Greil R, Markova J et al (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 11;385:1418–1427

    Google Scholar 

  35. Advani RH, Hoppe RT, Baer D, Mason J, Warnke R, Allen J et al (2013) Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol 24:1044–1048

    Article  CAS  PubMed  Google Scholar 

  36. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early stage Hodgkin’s disease: long-term results. J Clin Oncol 22:2835–2841

    Article  PubMed  Google Scholar 

  37. Thomas J, Fermé C, Noordijk EM, Morschhauser F, Girinsky T, Gaillard I et al (2018) Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORT-GELA H9-F intergroup randomized trial. Int J Radiat Oncol Biol Phys 100:1133–1145

    Article  PubMed  Google Scholar 

  38. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s lymphoma study group. J Clin Oncol 21:3601–3608

    Article  PubMed  Google Scholar 

  39. Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y et al (2006) Involved-node radiotherapy (INRT) in patients with early HL: concepts and guidelines. Radiother Oncol 79:270–277

    Article  PubMed  Google Scholar 

  40. Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78:1–5

    Article  PubMed  Google Scholar 

  41. Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Van Der Maazen R et al (2008) The conundrum of HL nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88:202–210

    Article  PubMed  Google Scholar 

  42. Campbell BA, Voss N, Pickles T, Morris J, Gascoyne RD, Savage KJ et al (2008) Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol 26:5170–5174

    Article  PubMed  Google Scholar 

  43. Longo DL, Glatstein E, Duffey PL, Young RC, Hubbard SM, Urba WJ et al (1991) Radiation therapy versus combination chemotherapy in the treatment of early stage Hodgkin’s disease: seven-year results of a prospective randomized trial. J Clin Oncol 9:906–917

    Article  CAS  PubMed  Google Scholar 

  44. Biti GP, Cimino G, Cartoni C, Magrini SM, Anselmo AP, Enrici RM et al (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I–IIA Hodgkin’s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 10:378–382

    Article  CAS  PubMed  Google Scholar 

  45. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN et al (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366:399–408

    Article  CAS  PubMed  Google Scholar 

  46. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C et al (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483–3489

    Article  CAS  PubMed  Google Scholar 

  47. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752

    Article  CAS  PubMed  Google Scholar 

  48. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in HL. Ann Oncol 16:1160–1168

    Article  CAS  PubMed  Google Scholar 

  49. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in HL. Blood 107:52–59

    Article  CAS  PubMed  Google Scholar 

  50. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M et al (2014) The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165:112–116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99:1107–1113

    Article  PubMed  PubMed Central  Google Scholar 

  52. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372:1598–1607

    Article  CAS  PubMed  Google Scholar 

  53. André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35:1786–1794

    Article  PubMed  Google Scholar 

  54. Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R et al (2019) Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol 37:2835–2845

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    Wouter Plattel

  2. Department of Haematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands

    Pieternella Lugtenburg

Authors
  1. Wouter Plattel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pieternella Lugtenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wouter Plattel .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University Hospital Cologne, Köln, Nordrhein-Westfalen, Germany

    Andreas Engert

  2. Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Plattel, W., Lugtenburg, P. (2020). Treatment of Early Favorable Hodgkin Lymphoma. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-32482-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-32482-7_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-32481-0

  • Online ISBN: 978-3-030-32482-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation